Literature DB >> 19760348

Intrathecal levels of IL-6 in Alzheimer's disease.

Kurt A Jellinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19760348     DOI： 10.1007/s00415-009-5312-2

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  9 in total

1.  Intra vitam lumbar and post mortem ventricular cerebrospinal fluid immunoreactive interleukin-6 in Alzheimer's disease patients.

Authors:  N Rösler; I Wichart; K A Jellinger
Journal:  Acta Neurol Scand       Date:  2001-02       Impact factor: 3.209

2.  Cerebrospinal fluid interleukin-6 levels: a possible marker of disease activity.

Authors:  K A Jellinger; N Rösler; I Wichart
Journal:  Ann Neurol       Date:  2001-12       Impact factor: 10.422

3.  Cerebrospinal fluid interleukin-6 levels in hypertensive encephalopathy: a possible marker of disease activity.

Authors:  T Takano; A Koyanagi; Y Osawa; T Taga; H Fujino
Journal:  Ann Neurol       Date:  2001-05       Impact factor: 10.422

4.  Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease.

Authors:  H Hampel; D Schoen; M J Schwarz; H U Kötter; C Schneider; T Sunderland; R Dukoff; J Levy; F Padberg; S Stübner; K Buch; N Müller; H J Möller
Journal:  Neurosci Lett       Date:  1997-06-13       Impact factor: 3.046

5.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

Authors:  D Blum-Degen; T Müller; W Kuhn; M Gerlach; H Przuntek; P Riederer
Journal:  Neurosci Lett       Date:  1995-12-29       Impact factor: 3.046

6.  Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients.

Authors:  P März; K Heese; C Hock; S Golombowski; F Müller-Spahn; S Rose-John; U Otten
Journal:  Neurosci Lett       Date:  1997-12-12       Impact factor: 3.046

7.  Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration.

Authors:  Daniela Galimberti; Eliana Venturelli; Chiara Fenoglio; Ilaria Guidi; Chiara Villa; Luigi Bergamaschini; Francesca Cortini; Diego Scalabrini; Pierluigi Baron; Carlo Vergani; Nereo Bresolin; Elio Scarpini
Journal:  J Neurol       Date:  2008-01-23       Impact factor: 4.849

8.  Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients.

Authors:  K Wada-Isoe; Y Wakutani; K Urakami; K Nakashima
Journal:  Acta Neurol Scand       Date:  2004-08       Impact factor: 3.209

9.  Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia.

Authors:  K Yamada; K Kono; H Umegaki; K Yamada; A Iguchi; T Fukatsu; N Nakashima; H Nishiwaki; Y Shimada; Y Sugita
Journal:  Neurosci Lett       Date:  1995-02-17       Impact factor: 3.046
  9 in total
  2 in total

Review 1.  Interleukin 6 and cognitive dysfunction.

Authors:  Isabel Trapero; Omar Cauli
Journal:  Metab Brain Dis       Date:  2014-04-30       Impact factor: 3.584

2.  Brain immune interactions and air pollution: macrophage inhibitory factor (MIF), prion cellular protein (PrP(C)), Interleukin-6 (IL-6), interleukin 1 receptor antagonist (IL-1Ra), and interleukin-2 (IL-2) in cerebrospinal fluid and MIF in serum differentiate urban children exposed to severe vs. low air pollution.

Authors:  Lilian Calderón-Garcidueñas; Janet V Cross; Maricela Franco-Lira; Mariana Aragón-Flores; Michael Kavanaugh; Ricardo Torres-Jardón; Chih-Kai Chao; Charles Thompson; Jing Chang; Hongtu Zhu; Amedeo D'Angiulli
Journal:  Front Neurosci       Date:  2013-10-10       Impact factor: 4.677
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.